Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929022 | PMC |
| http://dx.doi.org/10.1093/clinchem/hvab020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lifting the Burden of Sudden Cardiac Arrest Through International Collaboration: The PARQ Project (EU-COST Action).
JACC Adv
December 2024
Department of Clinical and Experimental Cardiology, Amsterdam University Medical Center, University of Amsterdam Amsterdam, the Netherlands.
Promotion of Cardiovascular Health in Africa: The Alliance for Medical Research in Africa (AMedRA) Expert Panel.
JACC Adv
December 2024
Alliance for Medical Research in Africa, Dakar, Senegal.
This proposed scientific statement is focused on providing new insights regarding challenges and opportunities for cardiovascular health (CVH) promotion in Africa. The statement includes an overview of the current state of CVH in Africa, with a particular interest in the cardiometabolic risk factors and their evaluation through metrics. The statement also explains the main principles of primordial prevention, its relevance in reducing noncommunicable disease and the different strategies that have been effective worldwide.
View Article and Find Full Text PDFCharacterization of preclinical models to investigate spinal cord stimulation for neuropathic pain: a systematic review and meta-analysis.
Pain Rep
February 2025
School of Pharmacy, Newcastle University, Newcastle-upon-Tyne, United Kingdom.
Despite advancements in preclinical and clinical spinal cord stimulation (SCS) research, the mechanisms of SCS action remain unclear. This may result from challenges in translatability of findings between species. Our systematic review (PROSPERO: CRD42023457443) aimed to comprehensively characterize the important translational components of preclinical SCS models, including stimulating elements and stimulation specifications.
View Article and Find Full Text PDFUnveiling neurocysticercosis: A call for heightened awareness and action.
Brain Spine
December 2024
Interdisciplinary Laboratory of Biotechnology and Health, Neurosciences and Cellular Physiology research team, Mohammed VI University of Sciences and Health (UM6SS), Casablanca, Morocco.
Inhalable Carbonyl Sulfide Donor-Hybridized Selective Phosphodiesterase 10A Inhibitor for Treating Idiopathic Pulmonary Fibrosis by Inhibiting Tumor Growth Factor-β Signaling and Activating the cAMP/Protein Kinase A/cAMP Response Element-Binding Protein (CREB)/p53 Axis.
ACS Pharmacol Transl Sci
January 2025
School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, P. R. China.
Idiopathic pulmonary fibrosis (IPF) is a debilitating, incurable, and life-threatening disease that lacks effective therapy. The overexpression of phosphodiesterase 10A (PDE10A) plays a vital role in pulmonary fibrosis (PF). However, the impact of selective PDE10A inhibitors on the tumor growth factor-β (TGF-β)/small mother against decapentaplegic (Smad) signaling pathway remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!